Beijing Sungen Biomedical Technology Co., Ltd
Clinical trials sponsored by Beijing Sungen Biomedical Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection could save heart muscle after attack Results expected Apr 2027 (estimated)
-
New drug SGT003 put to the test against Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…
Phase 1/2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New injection could save heart muscle after attack
Disease control Recruiting nowThis study tests a new medicine called SGC001 in people who have had a serious type of heart attack (anterior STEMI) and are scheduled for a procedure to open blocked arteries. The goal is to see if SGC001 can reduce the size of the heart damage and lower the chance of future hea…
Phase 2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC